Home Page

Fostering innovation and collaboration in liver research
About the Liver Center
The UCSF Liver Center is one of 17 Digestive Diseases Research Core Centers (DDRCC) in the United States, whose purpose is to enhance research productivity and collaboration among scientists with similar interests.
Learn More
Research Themes of the Center
The overall focus of the Center is on integrative biology of the liver. Research in the Center is organized into 3 themes: Liver Injury, Repair & Transplantation​, Hepatic Metabolism & Metabolic Derangements, Liver Cell Biology, Plasticity & Transformation​.
Learn More
Core Services of the Center
The Liver Center operates four biomedical core facilities to expedite and enhance the research performed by Center members. The Cores are designed to provide liver-specific services that are unavailable elsewhere within or outside UCSF.
Learn More

​Welcome to the UCSF Liver Center

The Liver Center is a consortium of more than 60 researchers who share a common interest in liver biology and disease. The goal of the Center is to integrate bench science with clinical investigation, in support of its vision to understand and cure human liver diseases.

The physicians and scientists of the Liver Center are committed to improving understanding of liver biology and alleviating suffering from liver diseases. Read More.

Jacquelyn Maher, MD

Program Director, Liver Center

 

Congratulations to the 2024 Annual Oral Presentation Awardees!

 

Pervinder Kaur Choksi, BS

Targeting biliary epithelial cells in healthy and chronically injured liver

Jin Ge, MD, MBA

Development of a liver disease-specific large language model chat interface using retrieval augumented genration

Mohammad Mehraban, PhD, MS

mir-432: a new chapter in TM6SF2 regulation

Congratulations to the 2024 Pilot & Feasibility Grant Awardees!

Arielle Klepper, MD, PhD

Immunologic and  Microbial Characterization of Ascites Fluid in Patients with Decompensated Cirrhosis

Amar Nijagal, MD

Deciphering the Role of Macrophage Mediated Signals on Immune Tolerance in the Developing Liver

Joni Nikkanen, PhD

Beyond Transcription: Post-translational Modifications in Controlling Sex-specific Hepatic Gene Programs

Garett R. Roll, MD, FACS

Study of Molecular Markers for Early Allograft Dysfunction in Liver Transplantation

Announcement from the Multinational Liver Societies: New “Fatty” Liver Disease Nomenclature That Is Affirmative And Non-Stigmatizing

Steatotic liver disease (SLD) is the new overarching term with metabolic dysfunction-associated steatotic liver disease (MASLD) replacing nohttp://pubmed.ncbi.nlm.nih.gov/38866344/nalcoholic fatty liver disease (NAFLD)    Read more

Featured Publications

Hsu BY, Driscoll J; Human cholangiocarcinogenesis project; Tateno C, Mattis AN, Kelley RK, Willenbring H. Human Hepatocytes Can Give Rise To Intrahepatic Cholangiocarcinomas. Gastroenterology. 2024 Jun 10: Epub ahead of print. PMID: 38866344; PMCID pending.

Li M, Wong D, Sack JS, Vogel AS, Hodi FS, Fong L, Lai JC, Zucker SD, Grover S.Outcomes of High-Grade Immune Checkpoint Inhibitor Hepatitis in Hospitalized and Nonhospitalized Patients. Clin Gastroenterol Hepatol. 2024 Jul;22(7):1444-1452.e4. doi: 10.1016/j.cgh.2024.02.006. Epub 2024 Feb 23. PMID: 38401693; PMCID: PMC11193617.

Deng S, Lu X, Wang X, Liang B, Xu H, Yang D, Cui G, Yonemura A, Paine H, Zhou Y, Zhang Y, Simile MM, Urigo F, Evert M, Calvisi DF, Green BL, Chen X. Overexpression of TBX3 suppresses tumorigenesis in experimental and human cholangiocarcinoma. Cell Death Dis. 2024 Jun 22;15(6):441. doi: 10.1038/s41419-024-06839-8. PMID: 38909034; PMCID: PMC11193761.

Rubin JB, Loeb R, Fenton C, Huang CY, Keyhani S, Seal KH, Lai JC. The burden of significant pain in the cirrhosis population: Risk factors, analgesic use, and impact on health care utilization and clinical outcomes. Hepatol Commun. 2024 Jun 1;8(6). PubMed PMID: 38780295; PubMed Central PMCID: PMC11124725.

For a complete list of liver-related member publications updated monthly, click here